About Enumera Molecular
Enumera Molecular is a Healthcare company based in Ann Arbor (United States) founded in 2022. Liquid biopsy tools are developed for biomolecule assessment. Enumera Molecular has raised $31.05 million across 2 funding rounds from investors including Arboretum Ventures. Its chief executive, as recorded, is Matthew Cooper. Enumera Molecular offers products and services including EnumeraPlex. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its competitors include Guardant Health, Natera and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Enumera Molecular was founded in 2022 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where liquid biopsy tools are manufactured to enable the assessment of biomolecules. Rapid and low-cost solutions are facilitated through these tools, supporting diagnostic applications in clinical and research settings. The companys efforts center on advancing non-invasive biomolecule analysis methods.
- Headquarters Ann Arbor, United States
- SectorsHealthcare
- Website enumeramolecular.com
- Social LinkedIn
- Total Equity Funding$31.05M (USD)
in 2 rounds
- Latest Funding Round$12.33M (USD), Series B
Jul 2026
- Investors
Products & Services of Enumera Molecular
Enumera Molecular offers a comprehensive portfolio of products and services, including EnumeraPlex.
Platform for simplified, rapid molecular counting in clinical diagnostics and genomics.
Funding Insights of Enumera Molecular
Enumera Molecular has successfully raised a total of $31.05M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $12.33 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.05M
- Total Rounds 2
- Last Round Series B — $12.33M
- First Round $18.72M
(May 2022)
- Investors Count 1
All 2 funding rounds of Enumera Molecular with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $12.33M | Series B | – | – | – |
| May 2022 | $18.72M | Series A | – | Arboretum Ventures | – |
1 investors in total: 1 institutional.
Investors in Enumera Molecular
Enumera Molecular has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Arboretum Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare venture capital investments are made by Arboretum Ventures. | arboretumvc.com | Ann Arbor, United States |
Investor details for Enumera Molecular
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enumera Molecular
1 people are tracked at Enumera Molecular (1 in leadership).
| Name | Role | Group |
|---|---|---|
Matthew Cooper | CEO | Leadership |
Complete people profiles for Enumera Molecular
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enumera Molecular
3 dated milestones of Enumera Molecular across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Enumera Molecular is founded.
- Funding First funding round of $18.7M.
- Funding Latest funding round, Series B, of $12.3M.
Competitors of Enumera Molecular
Enumera Molecular has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of Enumera Molecular
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enumera Molecular
Websites that share an audience with Enumera Molecular (enumeramolecular.com).
Websites whose visitors overlap most with Enumera Molecular. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| journeybio.life | 100% | View details | |||
| analiza.com | 97% | #9,918,228 | View details | ||
cbgbiotech.com | cbgbiotech.com | 92% | #3,660,146 | – | |
| forgebiologics.com | 81% | 9.9K | #2,600,767 | View details | |
immunospot.com | immunospot.com | 74% | #2,587,608 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Enumera Molecular
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as Enumera Molecular (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enumera Molecular
Complete news archive for Enumera Molecular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enumera Molecular
Enumera Molecular was founded in 2022.
Enumera Molecular is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Matthew Cooper is the CEO of Enumera Molecular, as recorded in our data.
Enumera Molecular is a funded company, having raised a total of $31.05M across 2 funding rounds to date. The company's 1st funding round was a Series A of $18.72M, raised on May 2022.
Enumera Molecular was founded in 2022 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where liquid biopsy tools are manufactured to enable the assessment of biomolecules. Rapid and low-cost solutions are facilitated through these tools, supporting diagnostic applications in clinical and research settings. The companys efforts center on advancing non-invasive biomolecule analysis methods.
Enumera Molecular's top competitors include Guardant Health, Foundation Medicine and Natera.
Enumera Molecular offers EnumeraPlex.
Enumera Molecular has 1 investor. Key investors include Arboretum Ventures.